Northwest & Ethical Investments’s Trillium Therapeutics Inc. TRIL Stock Holding History

Northwest & Ethical Investments’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,570	Closed	-$203K	–	456
2021 Q3	$203K	Buy	11,570 +597	+5%	+$6.97K	0.01%	367
2021 Q2	$106K	Buy	10,973 +7,350	+203%	+$69.2K	﹤0.01%	390
2021 Q1	$38.8K	Buy	3,623 +129	+4%	+$1.59K	﹤0.01%	396
2020 Q4	$51.4K	Buy	+3,494	New	+$50.4K	﹤0.01%	392

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Northwest & Ethical Investments's TRIL Position: Q4 2021 in Review

Northwest & Ethical Investments sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 11,570 shares — an estimated $203K sold.

Northwest & Ethical Investments first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $203K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Northwest & Ethical Investments reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Northwest & Ethical Investments sold 11,570 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $203K.
Northwest & Ethical Investments first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Northwest & Ethical Investments's Trillium Therapeutics Inc. position peaked at $203K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Northwest & Ethical Investments's 13F filing for Q4 2021, filed 9 Jul 2025.